Library of Slides and Posters

Effect of lopinavir (LPV) and ritonavir (RTV) dose adjustments on the pharmacokinetic (PK) interaction between LPV/RTV and tipranavir (TPV)
M Harris and others.


Significant Decrease in TMC125 Exposures when Co-administered with Tipranavir Boosted with Ritonavir in Healthy Subjects
M Schöller and others.


Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Pregnant Women and their Infants
J Rodman and others.


Steady-state Pharmacokinetic Evaluation of Emtricitabine in Neonates Exposed to HIV in utero
M Roberts and others.



The Safety of Tenofovir DF for the Treatment of HIV Infection: The First 4 Years.
M Nelson and others.


Low Atazanavir Concentrations in Cerebrospinal Fluid.
B Best and others.


Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006.
M Thompson and others.


In a Paired Sample Comparison, the Presence of Thymidine Analogue Mutations (TAMs), but not Other Common Nucleoside Reverse Transcriptase Inhibitor (NRTI) Mutations has a Differential Impact on Emtricitabine (FTC) and Lamivudine (3TC) Susceptibility.
L. Ross and others.


Lack of Effect of Acid Reducing Agents on the Pharmacokinetics (PK) of Lopinavir/Ritonavir (LPV/r) Tablet Formulation.
C Klein and others.


White Coat Compliance Patterns Make Therapeutic Drug Monitoring (TDM) a Potentially Unreliable Tool for Assessing Long-Term Drug Exposure.
T Podsadecki and others.


The HIV Integrase Inhibitor GS-9137 (JTK-303) Exhibits Potent Antiviral Activity in Treatment-Naïve and Experienced Patients.
E DeJesus and others.